Therapy Areas: Hereditary Disorders
5 November 2018 - United Kingdom-based Verona Pharma has completed patient enrolment for a phase two trial for its nebulised RPL554 as an add-on to dual therapy using long-acting anti-muscarinic/long-...
23 October 2018 - UK-based Vertex Pharmaceuticals (Europe) has received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for Kalydeco (...
11 October 2018 - - US-based inhaled glycopolymer-based therapeutics developer Synspira has been granted Orphan Designation by the United States Food and Drug Administration for poly (acetyl, arginyl)...
28 September 2018 - - US-based Decibel Therapeutics has obtained an exclusive, worldwide license to the development and commercialisation of ORC-13661, an oral medication developed by Oricula The...
21 September 2018 - - US-based glycopolymer-based therapeutics developer Synedgen has appointed Kaveri Parker, Ph.D. as chief business officer, the company said.

In her role, she will lea...
12 September 2018 - - FINCH 2, a global, randomised, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumat...
Related Headlines